Syncona CEO Martin Murphy discusses the $87 million Series A financing of Clade Therapeutics, which has been led by Syncona. Clade has been established with the aim of discovering and delivering scalable next generation induced pluripotent stem cell (iPSC)-derived medicines. It becomes the 12th company in the Syncona portfolio, and the sixth in the cell therapy space. 

Back to News and Insights